Only 5% of therapeutic interventions tested in animals gain regulatory approval for human use.
In the past two decades, stem-cell based models have emerged as efficient and predictive alternatives to traditional animal testing.
Despite growing interest, Indian industries have been hesitant to shift towards these New Approach Methodologies (NAMs). This brief argues that regulatory clarity, sustained translational funding, infrastructural support, and coordinated ecosystem-building can give researchers the confidence to invest: https://www.orfonline.org/expert-speak/nams-in-drug-testing-india-s-regulatory-recognition-is-not-enough
orfonline.org
NAMs in Drug Testing: India’s Regulatory Recognition Is Not Enough
September 8, 2026 216 1
